Anupam Rasayan India Limited has informed the Exchange about Investor Presentation
ANURAS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Anupam Rasayan India Limited has filed an investor presentation announcing the acquisition of Bliss GVS Pharma Limited for a controlling stake of 43.3-48.2% plus an open offer to public shareholders. Bliss GVS is a pharmaceutical formulations company with EU-GMP certification, manufacturing branded drugs across anti-malarial, anti-fungal, anti-bacterial, cardiovascular, anti-diabetic and other therapeutic segments. The target company has zero net debt, Rs 167 crore cash on balance sheet, and Rs 139 crore operating cash flow as of March 2026. Bliss GVS reported revenues of Rs 927 crore for FY26E with PAT of Rs 135 crore. Anupam plans to fund the deal with a term loan of Rs 300 crore and non-controlling non-voting equity. The acquisition will expand Anupam into new therapeutic areas, CDMO business for regulated markets, and offers significant synergy potential as Bliss GVS operates at only 30% capacity utilization.
This acquisition provides Anupam Rasayan with instant scale, a diversified product portfolio, and entry into regulated markets. The zero-debt target with strong cash generation reduces integration risk, while the Rs 300 crore debt financing will increase the acquirer's leverage. The significant capacity underutilization at Bliss GVS presents meaningful upside potential through cross-selling and operational improvements.